CONTRATOS DE INVESTIGACIÓN. ART. 83
Contract
Evaluation of the anti-CD160 antibodies in in vivo models.
Funder:
ELSALYS BIOTECH
date_range
Duration: from 18 May 2020 to 17 May 2021
(12 months)
Finished
euro
5,000.00 EUR
Of International (non-EU) scope.
Evaluation of the anti-CD160 antibodies in in vivo models.
Call:
(ELSALYS BIOTECH)
Researchers
Mª LUISA DEL
RÍO GONZÁLEZ
Leader
Publications related to the project
Show by type2022
-
The impact of CD160 deficiency on alloreactive CD8 T cell responses and allograft rejection
Translational Research